title: Minimizing the risk of posttransplant malignancy.
abstract: Nowadays cancer represents the second main cause of death in renal transplant patients with normal function of the graft. The incidence is 10 to 20 times higher than normal population. Calcineurin inhibitor therapy contributes to the increase in the development of neoplasia. Important evidence could bring a preventive effect of mammalian target of rapamycin in skin cancer, Kaposi's sarcoma, and renal cell carcinoma.
authors.affiliation: Nephrology and Renal Transplant Department, Hospital Clinic-University of Barcelona, Barcelona, Spain. jmcampis@clinic.ub.es
authors.forename: Josep M
authors.initials: JM
authors.lastname: Campistol
mesh_terms: D000368:Aged; D065095:Calcineurin Inhibitors; D002292:Carcinoma, Renal Cell / Q000517:prevention & control; D002423:Cause of Death; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000517:prevention & control; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology* / Q000401:mortality; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control; D011494:Protein Kinases / Q000627:therapeutic use; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000517:prevention & control; D020123:Sirolimus / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000517:prevention & control; D058570:TOR Serine-Threonine Kinases
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus